Paul Nouri, CFP
Hedge fund manager, long/short equity, healthcare

LipoScience Has Become Too Cheap To Ignore

Of the approximately $50 billion in IPOs this year, LipoScience (NASDAQ:LPDX) is indisputably one of the most disappointing and underperforming. After being priced at $9 in January of this year, the shares quickly rose to $11 and have since fallen nearly 70%.

Every quarter this year has brought on more disappointment. While the company's operating expenses will increase nearly 25% in 2013 over the prior year, sales are expected to decline approximately 5%. Also, average selling price for the test has declined for three consecutive years. So what reason could I have to recommend investors purchase shares of this diagnostic company?


LipoScience is a diagnostic company that develops and markets tests to identify the presence of cardiac...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details